Jeffrey R Strich
Overview
Explore the profile of Jeffrey R Strich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Strich J, Mishuk A, Diao G, Lawandi A, Li W, Demirkale C, et al.
Ann Intern Med
. 2024 Apr;
177(5):559-572.
PMID: 38639548
Background: The U.S. antibiotic market failure has threatened future innovation and supply. Understanding when and why clinicians underutilize recently approved gram-negative antibiotics might help prioritize the patient in future antibiotic...
12.
Lawandi A, Oshiro M, Warner S, Diao G, Strich J, Babiker A, et al.
Crit Care Med
. 2023 Dec;
52(1):e31-e33.
PMID: 38095531
No abstract available.
13.
Rhee C, Strich J, Chiotos K, Classen D, Cosgrove S, Greeno R, et al.
Clin Infect Dis
. 2023 Oct;
78(3):505-513.
PMID: 37831591
The Centers for Medicare & Medicaid Services (CMS) introduced the Severe Sepsis/Septic Shock Management Bundle (SEP-1) as a pay-for-reporting measure in 2015 and is now planning to make it a...
14.
Stein S, Platt A, Teague H, Anthony S, Reeder R, Cooper K, et al.
J Infect Dis
. 2023 Aug;
228(Suppl 7):S635-S647.
PMID: 37652048
Background: Existing models of Ebola virus infection have not fully characterized the pathophysiology of shock in connection with daily virologic, clinical, and immunologic parameters. We implemented a nonhuman primate critical...
15.
Lawandi A, Oshiro M, Warner S, Diao G, Strich J, Babiker A, et al.
Crit Care Med
. 2023 Jul;
51(11):1527-1537.
PMID: 37395622
Objectives: Serum procalcitonin is often ordered at admission for patients with suspected sepsis and bloodstream infections (BSIs), although its performance characteristics in this setting remain contested. This study aimed to...
16.
Sarzynski S, Lawandi A, Warner S, Demirkale C, Strich J, Dekker J, et al.
JAC Antimicrob Resist
. 2023 May;
5(2):dlad049.
PMID: 37124072
Background: Clinical data informing antimicrobial susceptibility breakpoints for infections are lacking. We sought to leverage real-world data to identify MIC values within the currently defined susceptible range that could discriminate...
17.
Strich J, Lawandi A, Warner S, Demirkale C, Sarzynski S, Babiker A, et al.
JAC Antimicrob Resist
. 2023 Apr;
5(2):dlad041.
PMID: 37034120
Introduction: A recent randomized trial has suggested an increased risk of mortality for ceftriaxone-non-susceptible Enterobacterales infections treated with piperacillin/tazobactam compared with meropenem despite MICs within the susceptible range. Methods: We...
18.
Huapaya J, Higgins J, Kanth S, Demirkale C, Gairhe S, Aboye E, et al.
J Infect Dis
. 2023 Feb;
228(1):46-58.
PMID: 36801946
Background: Data on cellular immune responses in persons with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following vaccination are limited. The evaluation of these patients with SARS-CoV-2 breakthrough infections...
19.
Wigerblad G, Warner S, Ramos-Benitez M, Kardava L, Tian X, Miao R, et al.
Sci Adv
. 2023 Jan;
9(1):eade8272.
PMID: 36598976
Spleen tyrosine kinase (SYK) is a previously unidentified therapeutic target that inhibits neutrophil and macrophage activation in coronavirus disease 2019 (COVID-19). Fostamatinib, a SYK inhibitor, was studied in a phase...
20.
Ramos-Benitez M, Strich J, Alehashemi S, Stein S, Rastegar A, de Jesus A, et al.
medRxiv
. 2022 Nov;
PMID: 36415460
Understanding early innate immune responses to coronavirus disease 2019 (COVID-19) is crucial to developing targeted therapies to mitigate disease severity. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection elicits interferon expression...